

**ASX Announcement**

5 November 2021

---

**Completion of \$20,000,000 Share Placement**

Antisense Therapeutics Limited [ASX: ANP | US OTC: ATHJY | FSE: AWY] (the "Company") today announced that it has completed a placement to raise \$20,000,000 through the issue of 83,333,332 fully paid ordinary shares in the Company ("Shares") at an issue price of \$0.24 per Share to institutional and sophisticated investors.

Please refer to the accompanying Appendix 2A which contains further details.

**Notice Under Section 708A (5) (e) of the Corporations Act 2001**

Antisense Therapeutics Limited gives notice under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (the "Corporations Act") that:

1. On 5 November 2021 the Company issued 83,333,332 Shares in respect of a placement.
2. The Company issued those Shares without disclosure to investors under Part 6D.2 of the Corporations Act.
3. The Company is providing this notice under section 708A (5)(e) of the Corporations Act.
4. As at the date of this notice the Company has complied with:
  - i. The provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
  - ii. Section 674 of the Corporations Act.
5. As at the date of this notice there is no "excluded information" (as defined in subsection 708A (7) and subsection 708A (8) of the Corporations Act) which is required to be disclosed by the Company.

*This announcement has been authorised for release by the Board.*

**For more information please contact:****Antisense Therapeutics**

Mark Diamond  
Managing Director  
+61 (0)3 9827 8999  
[www.antisense.com.au](http://www.antisense.com.au)

**Investment Enquiries**

Gennadi Koutchin  
XEC Partners  
[gkoutchin@xecpartners.com.au](mailto:gkoutchin@xecpartners.com.au)  
1300 932 037